PA-824: Bicyclic Nitroimidazole for Drug-Resistant Tuberculosis Research

Executive Summary: PA-824 (CAS 187235-37-6) is a bicyclic nitroimidazole compound exhibiting potent, verifiable anti-mycobacterial activity (MIC 0.015–0.25 μg/ml) against both replicating and non-replicating Mycobacterium tuberculosis, including drug-resistant strains (Nurlilah Ab Rahman et al., 2026). Its mechanism combines inhibition of ketomycolate biosynthesis with enzymatic nitro-reduction, releasing intracellular nitric oxide that is lethal to mycobacteria. PA-824's dual-action profile distinguishes it from traditional anti-tuberculosis drugs by targeting both cell wall integrity and respiratory pathways. The compound is DMSO-soluble (≥17.85 mg/mL), stable at -20°C, and provided by APExBIO at ≥98% purity, supporting robust research workflows (APExBIO). Peer-reviewed evidence underscores its value for MIC determination, synergy studies, and next-generation therapeutic investigations (Nurlilah Ab Rahman et al., 2026).

Biological Rationale

Tuberculosis (TB) remains a leading cause of infectious disease mortality worldwide, with multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains presenting major challenges (Nurlilah Ab Rahman et al., 2026). Mycobacterium tuberculosis persists in both replicating and non-replicating forms, the latter often being tolerant to conventional antibiotics. Targeting cell wall biosynthesis and energy production pathways is critical for sterilizing infections and preventing relapse. PA-824, a bicyclic nitroimidazole derivative, has emerged as a benchmark compound, demonstrating bactericidal activity against both drug-sensitive and drug-resistant M. tuberculosis populations. Its utility in research and development is further supported by high-purity supply, comprehensive quality control, and compatibility with established tuberculosis model systems (APExBIO).

Mechanism of Action of PA-824

PA-824 acts through a dual mechanism:

• Inhibition of Ketomycolate Biosynthesis: PA-824 blocks the formation of ketomycolic acids, essential components of the mycobacterial cell wall, impairing cell wall integrity (Nurlilah Ab Rahman et al., 2026).
• Intracellular Nitric Oxide Release: Following nitro-reduction by mycobacterial enzymes, PA-824 generates nitric oxide (NO) within the bacterium. NO disrupts the electron transport chain, targeting both cytochrome bcc:aa3 and bd oxidases, leading to bactericidal effects especially on non-replicating, antibiotic-tolerant subpopulations (Nurlilah Ab Rahman et al., 2026).

This dual action means PA-824 can kill M. tuberculosis populations that evade standard therapies. Unlike single-target drugs, it impairs both cell wall biosynthesis and energy metabolism, reducing risk of resistance emergence. The compound has no significant activity against non-mycobacterial organisms under standard laboratory conditions (APExBIO).

Evidence & Benchmarks

• PA-824 exhibits MIC values between 0.015 μg/ml and 0.25 μg/ml against laboratory and clinical isolates of M. tuberculosis in Middlebrook 7H9 broth at 37°C (Nurlilah Ab Rahman et al., 2026).
• IC₅₀ for inhibition of mycobacterial growth is less than 2.8 μM under standard culture conditions (APExBIO).
• Active against both replicating and non-replicating M. tuberculosis in hypoxic and nutrient-limited models (Nurlilah Ab Rahman et al., 2026).
• Demonstrates synergy in vitro and in vivo with cytochrome bcc:aa3 inhibitors (e.g., telacebec/Q203) and cytochrome bd oxidase inhibitors (ND-011992) (Nurlilah Ab Rahman et al., 2026).
• PA-824 is supplied with ≥98% purity, supported by HPLC, NMR, and MSDS documentation (APExBIO).

For a detailed, practical guide to leveraging PA-824 in advanced research workflows, see PA-824: Bicyclic Nitroimidazole for Drug-Resistant Tuberc.... This article extends those discussions by incorporating the latest clinical synergy findings and benchmark MIC ranges.

Applications, Limits & Misconceptions

PA-824 is primarily a tool for research in tuberculosis drug development and mechanism-of-action studies. Its dual-action mechanism enables:

• Assessment of bactericidal activity against drug-resistant and latent M. tuberculosis populations.
• Synergy studies with other respiratory inhibitors and cell wall-active agents.
• MIC determination, time-kill kinetics, and resistance emergence studies.
• Development of next-generation regimens targeting both cell wall and energy metabolism (Nurlilah Ab Rahman et al., 2026).

This guide clarifies and updates earlier summaries, such as PA-824: Bicyclic Nitroimidazole for Drug-Resistant Tuberc..., by providing recent synergy benchmarks and explicit limitations in non-mycobacterial systems.

Common Pitfalls or Misconceptions

• PA-824 is not active against non-mycobacterial pathogens under standard conditions.
• It does not replace frontline therapy in clinical treatment; it is for research use only.
• Reduced solubility in water and ethanol (<0.1 mg/mL); DMSO is required for effective stock solutions.
• Solutions are stable for short-term use only; long-term storage must be at -20°C (APExBIO).
• Synergy with other agents (e.g., Q203, ND-011992) is context-dependent and must be empirically validated (Nurlilah Ab Rahman et al., 2026).

For workflow troubleshooting and comparative applications, refer to PA-824: Bicyclic Nitroimidazole Derivative for Tuberculos.... This article clarifies boundaries in solubility and compound stability not covered previously.

Workflow Integration & Parameters

Researchers should prepare PA-824 stock solutions in DMSO at ≥17.85 mg/mL. Working dilutions should be made immediately prior to use. All manipulations must occur under sterile conditions. Store dry powder at -20°C in tightly capped vials to maintain ≥98% purity. MIC determinations require Middlebrook 7H9 broth (pH 6.8) at 37°C for 7–14 days. For synergy studies, combine with complementary respiratory or cell wall inhibitors, guided by published combination protocols (Nurlilah Ab Rahman et al., 2026).

APExBIO provides the A1736 kit with full quality control documentation. For an overview of workflow compatibility and troubleshooting, PA-824: Bicyclic Nitroimidazole for Drug-Resistant Tuberc... details stepwise integration strategies. This article updates those protocols with recent stability and storage findings.

Conclusion & Outlook

PA-824 is a validated research tool for dissecting mycobacterial cell wall and respiratory vulnerabilities. Its dual-action mechanism, high purity, and robust documentation support its ongoing use in tuberculosis drug development, with particular value for studies of drug-resistant and latent infections. Recent synergy data with terminal oxidase inhibitors highlight its potential in rational drug regimen design (Nurlilah Ab Rahman et al., 2026). For product details, visit the PA-824 product page at APExBIO.